A Phase 3 interventional study of Abatacept and Methotrexate in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 201 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-28.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 6th largest by enrollment, is one of 3 that started in 2015, is one of 26 in phase 3, and was the 43rd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 994 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2015, is one of 22 in phase 3, and was the 61st registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if abatacept is effective in the treatment of early rheumatoid arthritis.
Subcutaneous (SC)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
Drug: Abatacept · Drug: Methotrexate
Methotrexate at least 15mg per week tablet or capsule orally
Drug: Methotrexate
Placebo for Abatacept subcutaneous injection once per week
Other: Abatacept Placebo
Placebo to match Methotrexate capsule orally once per week
Other: Methotrexate Placebo
Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24
Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI \<= 3.3. Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \>26 = high disease activity.
Time frame: Week 24
Percentage of Participants in Disease Activity Score (DAS)28 - C-reactive Protein (CRP) Remission at Week 24
DAS28-CRP = Disease Activity Score 28 based on C-reactive protein DAS28-CRP Remission is defined as DAS28-CRP \<= 2.6 Using a logistic regression model that includes treatment arm, stratification variable and baseline measure as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided.
Time frame: Week 24
Percentage of Participants in SDAI Remission at Week 52
Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI \<= 3.3. Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \>26 = high disease activity.
Time frame: Week 52
Mean Change From Baseline in Radiographic Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijide Total Sharp Scores (TSS) at Week 52
The Modified Total Sharp Score (mTSS) is calculated as the bilateral sum of erosion and Joint Space Narrowing (JSN) scores across all joints of the hands and feet.The score range for mTSS is 0-448. Higher scores indicate more joint damage. The mean change from baseline in TSS using modified Sharp/van der Heijide scores was assessed using a rank-based nonparametric ANCOVA model.
Time frame: Week 52
Percentage of Participants in Boolean Remission at Week 52
Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale). Logistic regression was used for this endpoint.
Time frame: Week 52
| Milestone | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Abatacept + Methotrexate (De-Escalation Period) | Abatacept (End of Week) + Methotrexate (De-Escalation Period) | Abatacept Monotherapy (De-Escalation Period) | Methotrexate Monotherapy (De-Escalation Period) | Abatacept + Methotrexate (Open Label Period) | Abatacept + Methotrexate (Open Label Extension Period) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 451 | 301 | 242 | 0 | 0 | 0 | 0 | 0 | 0 |
| Induction to open label | 289 | 196 | 147 | 0 | 0 | 0 | 0 | 0 | 0 |
| Early escaped to open label | 10 | 21 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Induction to de-escalation | 94 | 37 | 53 | 0 | 0 | 0 | 0 | 0 | 0 |
| Randomized in de-escalation period | 0 | 0 | 0 | 50 | 50 | 47 | 37 | 0 | 0 |
| De-escalation to open label extension | 0 | 0 | 0 | 36 | 30 | 32 | 22 | 0 | 0 |
| Early escaped de-escalation to open label period | 0 | 0 | 0 | 2 | 5 | 4 | 3 | 0 | 0 |
| Open label and open label extension period | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 685 | 120 |
| Completed | 388 | 233 | 201 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 63 | 68 | 41 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 18 | 8 | 14 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent | 11 | 10 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 6 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject request to discontinue | 11 | 3 | 6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: No longer meets study criteria | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 11 | 35 | 9 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Poor/non-compliance | 3 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Not disclosed | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI \<= 3.3. Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \>26 = high disease activity.
| Percentage of participants | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Abatacept + Methotrexate (De-Escalation Period) | Abatacept (End of Week) + Methotrexate (De-Escalation Period) | Abatacept Monotherapy (De-Escalation Period) | Methotrexate Monotherapy (De-Escalation Period) | Abatacept + Methotrexate (Open Label Period) | Abatacept + Methotrexate (Open Label Extension Period) |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants in Simple Disease Activity Index (SDAI) Remission at Week 24 | 21.3 (16.0 to 26.7) | 16.0 (10.1 to 21.9) | — | — | — | — | — | — | — |
DAS28-CRP = Disease Activity Score 28 based on C-reactive protein DAS28-CRP Remission is defined as DAS28-CRP \<= 2.6 Using a logistic regression model that includes treatment arm, stratification variable and baseline measure as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided.
| Percentage of Participants | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Abatacept + Methotrexate (De-Escalation Period) | Abatacept (End of Week) + Methotrexate (De-Escalation Period) | Abatacept Monotherapy (De-Escalation Period) | Methotrexate Monotherapy (De-Escalation Period) | Abatacept + Methotrexate (Open Label Period) | Abatacept + Methotrexate (Open Label Extension Period) |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants in Disease Activity Score (DAS)28 - C-reactive Protein (CRP) Remission at Week 24 | 38.7 (32.3 to 45.0) | 25.3 (18.4 to 32.3) | — | — | — | — | — | — | — |
Simple Disease Activity Index (SDAI) is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP (TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL) SDAI Remission is defined as SDAI \<= 3.3. Using a logistic regression model that includes treatment arm, randomization stratification factor, and baseline SDAI as continuous variable and point estimate of adjusted ORs, corresponding 95% CI and p-value was provided. SDAI total score range: 0 to 86. SDAI \<= 3.3 indicates disease remission and SDAI \>26 = high disease activity.
| Percentage of participants | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Abatacept + Methotrexate (De-Escalation Period) | Abatacept (End of Week) + Methotrexate (De-Escalation Period) | Abatacept Monotherapy (De-Escalation Period) | Methotrexate Monotherapy (De-Escalation Period) | Abatacept + Methotrexate (Open Label Period) | Abatacept + Methotrexate (Open Label Extension Period) |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants in SDAI Remission at Week 52 | 29.8 (23.8 to 35.8) | 15.3 (9.6 to 21.1) | — | — | — | — | — | — | — |
The Modified Total Sharp Score (mTSS) is calculated as the bilateral sum of erosion and Joint Space Narrowing (JSN) scores across all joints of the hands and feet.The score range for mTSS is 0-448. Higher scores indicate more joint damage. The mean change from baseline in TSS using modified Sharp/van der Heijide scores was assessed using a rank-based nonparametric ANCOVA model.
| Total Sharp Score | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Abatacept + Methotrexate (De-Escalation Period) | Abatacept (End of Week) + Methotrexate (De-Escalation Period) | Abatacept Monotherapy (De-Escalation Period) | Methotrexate Monotherapy (De-Escalation Period) | Abatacept + Methotrexate (Open Label Period) | Abatacept + Methotrexate (Open Label Extension Period) |
|---|---|---|---|---|---|---|---|---|---|
| Mean Change From Baseline in Radiographic Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijide Total Sharp Scores (TSS) at Week 52 | 0.53 ± 2.279 | 2.52 ± 6.205 | — | — | — | — | — | — | — |
Boolean Remission is defined as Tender joint count less than 1, Swollen joint count less than 1, CRP less than 1 mg/dL, patient global assessment less than 1 (on 0 to 10 VAS scale). Logistic regression was used for this endpoint.
| Percentage of participants | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Abatacept + Methotrexate (De-Escalation Period) | Abatacept (End of Week) + Methotrexate (De-Escalation Period) | Abatacept Monotherapy (De-Escalation Period) | Methotrexate Monotherapy (De-Escalation Period) | Abatacept + Methotrexate (Open Label Period) | Abatacept + Methotrexate (Open Label Extension Period) |
|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants in Boolean Remission at Week 52 | 21.5 (17.7 to 25.3) | 11.6 (8.0 to 15.2) | — | — | — | — | — | — | — |
Collected over approximately 54 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | 1/451 (0.2%) | 32/451 (7.1%) | 237/451 (52.5%) |
| Placebo + Methotrexate (Cohort 1, IP) | 1/301 (0.3%) | 9/301 (3%) | 152/301 (50.5%) |
| Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | 0/242 (0%) | 23/242 (9.5%) | 123/242 (50.8%) |
| Abatacept + Methotrexate (De-Escalation Period) | 0/50 (0%) | 3/50 (6%) | 12/50 (24%) |
| Abatacept (End of Week) + Methotrexate (De-Escalation Period) | 1/50 (2%) | 3/50 (6%) | 22/50 (44%) |
| Abatacept Monotherapy (De-Escalation Period) | 0/47 (0%) | 0/47 (0%) | 10/47 (21.3%) |
| Methotrexate Monotherapy (De-Escalation Period) | 0/37 (0%) | 0/37 (0%) | 16/37 (43.2%) |
| Abatacept + Methotrexate (Open Label Period) | 1/685 (0.1%) | 40/685 (5.8%) | 230/685 (33.6%) |
| Abatacept + Methotrexate (Open Label Extension Period) | 0/120 (0%) | 0/120 (0%) | 15/120 (12.5%) |
| Event | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Abatacept + Methotrexate (De-Escalation Period) | Abatacept (End of Week) + Methotrexate (De-Escalation Period) | Abatacept Monotherapy (De-Escalation Period) | Methotrexate Monotherapy (De-Escalation Period) | Abatacept + Methotrexate (Open Label Period) | Abatacept + Methotrexate (Open Label Extension Period) |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatitis acuteGastrointestinal disorders | 0/451 | 0/301 | 0/242 | 0/50 | 1/50 | 0/47 | 0/37 | 0/685 | 0/120 |
| PyrexiaGeneral disorders | 0/451 | 0/301 | 0/242 | 0/50 | 1/50 | 0/47 | 0/37 | 0/685 | 0/120 |
| CholelithiasisHepatobiliary disorders | 0/451 | 0/301 | 0/242 | 1/50 | 0/50 | 0/47 | 0/37 | 1/685 | 0/120 |
| Infectious mononucleosisInfections and infestations | 0/451 | 0/301 | 0/242 | 0/50 | 1/50 | 0/47 | 0/37 | 0/685 | 0/120 |
| PneumoniaInfections and infestations | 2/451 | 2/301 | 1/242 | 0/50 | 1/50 | 0/47 | 0/37 | 2/685 | 0/120 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/451 | 0/301 | 0/242 | 1/50 | 0/50 | 0/47 | 0/37 | 0/685 | 0/120 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/451 | 0/301 | 1/242 | 0/50 | 1/50 | 0/47 | 0/37 | 0/685 | 0/120 |
| Knee operationSurgical and medical procedures | 0/451 | 0/301 | 0/242 | 1/50 | 0/50 | 0/47 | 0/37 | 0/685 | 0/120 |
| Cholecystitis acuteHepatobiliary disorders | 1/451 | 0/301 | 2/242 | 0/50 | 0/50 | 0/47 | 0/37 | 1/685 | 0/120 |
| Urinary tract infectionInfections and infestations | 2/451 | 1/301 | 1/242 | 0/50 | 0/50 | 0/47 | 0/37 | 0/685 | 0/120 |
| Event | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Abatacept + Methotrexate (De-Escalation Period) | Abatacept (End of Week) + Methotrexate (De-Escalation Period) | Abatacept Monotherapy (De-Escalation Period) | Methotrexate Monotherapy (De-Escalation Period) | Abatacept + Methotrexate (Open Label Period) | Abatacept + Methotrexate (Open Label Extension Period) |
|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 63/451 | 43/301 | 36/242 | 2/50 | 6/50 | 4/47 | 5/37 | 59/685 | 6/120 |
| BronchitisInfections and infestations | 19/451 | 12/301 | 16/242 | 3/50 | 6/50 | 1/47 | 0/37 | 24/685 | 1/120 |
| NauseaGastrointestinal disorders | 42/451 | 24/301 | 22/242 | 1/50 | 2/50 | 0/47 | 1/37 | 23/685 | 0/120 |
| Upper respiratory tract infectionInfections and infestations | 24/451 | 16/301 | 18/242 | 1/50 | 2/50 | 1/47 | 3/37 | 28/685 | 3/120 |
| HeadacheNervous system disorders | 31/451 | 21/301 | 8/242 | 0/50 | 1/50 | 1/47 | 1/37 | 20/685 | 0/120 |
| GastroenteritisInfections and infestations | 13/451 | 9/301 | 10/242 | 0/50 | 3/50 | 1/47 | 2/37 | 13/685 | 1/120 |
| Aspartate aminotransferase increasedInvestigations | 14/451 | 10/301 | 9/242 | 3/50 | 0/50 | 0/47 | 0/37 | 11/685 | 0/120 |
| HypertensionVascular disorders | 11/451 | 8/301 | 5/242 | 0/50 | 3/50 | 0/47 | 0/37 | 4/685 | 0/120 |
| StomatitisGastrointestinal disorders | 27/451 | 8/301 | 1/242 | 0/50 | 1/50 | 2/47 | 2/37 | 21/685 | 2/120 |
| AnaemiaBlood and lymphatic system disorders | 12/451 | 18/301 | 4/242 | 1/50 | 1/50 | 0/47 | 1/37 | 10/685 | 1/120 |
| Age, Continuous(years) | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Total |
|---|---|---|---|---|
| Mean | 48.9 ± 12.74 | 48.8 ± 13.99 | 50.0 ± 12.91 | 49.1 ± 13.17 |
| Sex: Female, Male(Participants) | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Total |
|---|---|---|---|---|
| Female | 349 | 243 | 189 | 781 |
| Male | 102 | 58 | 53 | 213 |
| Race/Ethnicity, Customized(Participants) | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Total |
|---|---|---|---|---|
| WHITE | 315 | 209 | 174 | 698 |
| BLACK/AFRICAN AMERICAN | 20 | 16 | 7 | 43 |
| AMERICAN INDIAN/ALASKA NATIVE | 0 | 3 | 1 | 4 |
| ASIAN | 77 | 52 | 11 | 140 |
| RACE - OTHER/ NOT REPORTED | 39 | 21 | 49 | 109 |
| HISPANIC OR LATINO | 8 | 5 | 9 | 22 |
| NOT HISPANIC OR LATINO | 43 | 37 | 32 | 112 |
| ETHNICITY - NOT REPORTED | 400 | 259 | 201 | 860 |
| MODIFIED SHARP/VAN DER HEIJDE TOTAL SCORE (mTSS)(Scores on a scale) | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Total |
|---|---|---|---|---|
| Mean | 9.82 ± 16.342 | 12.99 ± 19.769 | — | 11.08 ± 17.839 |
| Tender Joints - 28(Joint Count) | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Total |
|---|---|---|---|---|
| Mean | 13.2 ± 6.76 | 13.7 ± 6.77 | — | 13.4 ± 6.76 |
| Swollen Joints - 28(Joint Count) | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Total |
|---|---|---|---|---|
| Mean | 10.0 ± 5.71 | 10.7 ± 5.85 | — | 10.3 ± 5.77 |
| Subject global assessment of disease activity(mm) | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Total |
|---|---|---|---|---|
| Mean | 65.7 ± 22.7 | 62.7 ± 24.05 | — | 64.5 ± 23.28 |
| Physician global assessment of disease activity(mm) | Combination Therapy: Abatacept + Methotrexate (Cohort 1, IP) | Placebo + Methotrexate (Cohort 1, IP) | Combination Therapy: Abatacept + Methotrexate (Cohort 2, IP) | Total |
|---|---|---|---|---|
| Mean | 65.1 ± 18.48 | 66.1 ± 19.75 | — | 65.5 ± 18.99 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 201 sites across 31 countries. Choose a country and city above to see the rest.
Ran from Sep 2015 to primary completion in Jan 2017, 16 months.
Results were first posted in Apr 2019, 2 years 2 months after primary completion. A results delay was requested in Dec 2017.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 16 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abatacept · Methotrexate